Roth Capital Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

Stock analysts at Roth Capital began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report issued on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $113.00 price target on the stock. Roth Capital‘s target price would suggest a potential upside of 42.44% from the stock’s previous close.

Several other analysts have also recently issued reports on DNTH. Citigroup began coverage on Dianthus Therapeutics in a research report on Friday, September 4th. They set a “buy” rating and a $156.00 target price for the company. Truist Financial raised their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $158.00 price target on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Wedbush upped their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $128.54.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $79.33 on Tuesday. Dianthus Therapeutics has a fifty-two week low of $32.28 and a fifty-two week high of $117.88. The company has a 50 day simple moving average of $95.29 and a two-hundred day simple moving average of $83.74. The company has a market capitalization of $4.35 billion, a price-to-earnings ratio of -19.12 and a beta of 1.35.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. On average, analysts forecast that Dianthus Therapeutics will post -3.81 earnings per share for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $425,640. This represents a 85.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Simon Read sold 2,778 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the sale, the director owned 2,778 shares in the company, valued at $326,553.90. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 242,429 shares of company stock valued at $26,118,913 over the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Several large investors have recently modified their holdings of DNTH. First Horizon Corp bought a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at approximately $32,000. EFG International AG purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $49,000. GAMMA Investing LLC boosted its position in Dianthus Therapeutics by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after acquiring an additional 254 shares during the period. Global Retirement Partners LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter worth approximately $93,000. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Dianthus Therapeutics by 75.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company’s stock valued at $93,000 after buying an additional 453 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.